Importance of bone turnover for therapeutic decisions in patients with CKD-MBD.

Bone Density Conservation Agents / therapeutic use Bone Diseases Bone Remodeling Chronic Kidney Disease-Mineral and Bone Disorder / drug therapy Humans

Journal

Kidney international
ISSN: 1523-1755
Titre abrégé: Kidney Int
Pays: United States
ID NLM: 0323470

Informations de publication

Date de publication:
09 2021
Historique:
received: 29 04 2021
revised: 24 05 2021
accepted: 26 05 2021
entrez: 23 8 2021
pubmed: 24 8 2021
medline: 26 8 2021
Statut: ppublish

Résumé

Patients with chronic kidney disease-mineral and bone disorder (CKD-MBD) frequently have low bone formation rates. A recent review suggested that adynamic bone disease is not always associated with negative outcomes and therefore antiresorptive medications could be used more often. However, there is currently no evidence to support an improvement in fracture risk or mortality in patients with CKD-MBD and low bone turnover who are treated with antiresorptive medication. There is reasonable pathophysiological evidence suggesting that it may even be harmful.

Identifiants

DOI: 10.1016/j.kint.2021.05.024 PMID: 34420656
pubmed: 34420656
pii: S0085-2538(21)00568-8
doi: 10.1016/j.kint.2021.05.024
pii:
doi:

Substances chimiques

Bone Density Conservation Agents 0

Types de publication

Journal Article Comment

Langues

eng

Sous-ensembles de citation

IM

Pagination

502-505

Commentaires et corrections

Type : CommentOn

Informations de copyright

Copyright © 2021 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Auteurs

Susan M Ott (SM)

Department of Medicine, University of Washington, Seattle, Washington, USA. Electronic address: smott@u.washington.edu.

Hartmut H Malluche (HH)

Division of Nephrology Bone and Mineral Metabolism, University of Kentucky, Lexington, Kentucky, USA.

Vanda Jorgetti (V)

Faculdade de Medicina, Hospital das Clínicas, Laboratório de Fisiopatologia Renal, Universidade de São Paulo, São Paulo, São Paulo, Brazil.

Grahame J Elder (GJ)

Department of Renal Medicine, Westmead Hospital, Westmead, New South Wales, Australia; Osteoporosis and Bone Biology Division, Garvan Institute for Medical Research, Darlinghurst, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Agents de maintien de la densité osseuse › Importance of bone turnover for therapeutic...
questionsmedicales.fr › Maladies ostéomusculaires › Maladies osseuses › Importance of bone turnover for therapeutic...
questionsmedicales.fr › Phénomènes biologiques › Régénération › Remodelage osseux › Importance of bone turnover for therapeutic...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Ostéodystrophie rénale › Importance of bone turnover for therapeutic...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Importance of bone turnover for therapeutic...